1. Home
  2. GIGM vs DYAI Comparison

GIGM vs DYAI Comparison

Compare GIGM & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GIGM

GigaMedia Limited

HOLD

Current Price

$1.38

Market Cap

15.8M

Sector

Technology

ML Signal

HOLD

Logo Dyadic International Inc.

DYAI

Dyadic International Inc.

HOLD

Current Price

$0.42

Market Cap

17.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIGM
DYAI
Founded
1998
1979
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.8M
17.0M
IPO Year
2002
2026

Fundamental Metrics

Financial Performance
Metric
GIGM
DYAI
Price
$1.38
$0.42
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
4.0K
192.2K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,090,345.00
Revenue This Year
N/A
$122.79
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$0.34
52 Week High
$1.84
$1.60

Technical Indicators

Market Signals
Indicator
GIGM
DYAI
Relative Strength Index (RSI) 48.61 25.71
Support Level $1.37 N/A
Resistance Level $1.54 $0.90
Average True Range (ATR) 0.09 0.07
MACD -0.00 0.00
Stochastic Oscillator 75.68 30.35

Price Performance

Historical Comparison
GIGM
DYAI

About GIGM GigaMedia Limited

GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.

About DYAI Dyadic International Inc.

Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Share on Social Networks: